The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Of a snowballing demand for Angle's services analysing circulating tumour cells.
Big agreements this year:-
1. 2nd January. Eisai Inc. (15 Billion $ market cap). Announcement was regarding the ***HER2 protein***.
Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies.
https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html
2. 24th April. Astrazeneca Plc ($211 billion market cap). Announcement was regarding micronuclei detection based on its existing pKAP1 CTC-based DDR assay.
Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html
3. 3rd May. Astrazeneca Plc ($211 billion market cap). Announcement was to develop an Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.
Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html
The above announcements are fantastically good for Angle. However, if the market can also see demand for the announcement of the 4th Jan the sp will truly take off IMHO.
This was regarding the Combined DNA Next Generation Sequencing of CTCs and CtDna from the same blood sample test.
It compares the CtDna (DNA fragments found in the general blood) with the DNA of the circulating cancer cells the Parsortix machine can catch.
Angle have found unexpected variations between the two indicating CtDna analysis alone sometimes misses vital information.
This test can be used in ***ANY cancer drug trial involving ANY type of cancer which has metastasised***, and clearly gives additional important information.
I believe it may become a part of the ***standard analysis*** during cancer drug trials involving metastasised cancer.
All IMHO.
Of a snowballing demand for Angle's services analysing circulating tumour cells.
Agreements this year:-
1. 2nd January. Eisai Inc. (15 Billion $ market cap). Announcement was regarding the ***HER2 protein***.
Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies.
https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html
2. 24th April. Astrazeneca Plc ($211 billion market cap). Announcement was regarding micronuclei detection based on its existing pKAP1 CTC-based DDR assay.
Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html
3. 3rd May. Astrazeneca Plc ($211 billion market cap). Announcement was to develop an Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.
Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.
https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html
The above announcements are fantastically good for Angle. However, if the market can also see demand for the announcement of the 4th Jan the sp will truly take off IMHO.
This was regarding the Combined DNA Next Generation Sequencing of CTCs and CtDna from the same blood sample test.
It compares the CtDna (DNA fragments found in the general blood) with the DNA of the circulating cancer cells the Parsortix machine can catch.
Angle have found unexpected variations between the two indicating CtDna analysis alone sometimes misses vital information.
This test can be used in ***ANY cancer drug trial involving ANY type of cancer which has metastasised***.
I believe it may become a part of the ***standard analysis*** during cancer drug trials involving metastasised cancer
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.ht
Excellent post Mr Carrot
Picathartes.
"Excellent post Mr Carrot".
============================
Thanks.
There are 48 Pharma Co's in the World that have larger market caps than Eisai Inc. (15 billion $). In view of that it seems probable that Angle Plc are going to get a lot more orders to analyse the circulating tumour cells their Parsortix machine can catch, 99% of them live, ideal for testing. One would have thought they will be inundated with enquiries? Time will tell.
All IMHO.
Carrot
FFS stop this reiterative rubbish; it is a terrible waste of space, and achieves absolutely nothing.